Articles tagged with Lung Cancer
A Phase II clinical trial has demonstrated a 46.5% objective response rate to tepotinib in patients with advanced non-small cell lung cancer and the MET exon 14 skipping mutation. The study's findings provide a new treatment option for this elderly population, with a durable response lasting almost one year.
The International Association for the Study of Lung Cancer found that molecular testing rates for lung cancer are less than 50% in most countries. The most frequent barrier to testing was cost, followed by quality/standards and access.
PD-1/PD-L1 inhibitors have shown promise in treating non-small cell lung cancer, but the proportion of patients who benefit from these treatments is relatively small. Researchers are exploring biomarkers to identify potential beneficiaries and improve cost-effectiveness.
A new lung cancer screening cohort study demonstrates low adverse event rates and detects 70% of diagnosed cases at early stages. Family medicine plays a critical role in expanding lung cancer screenings to underserved populations.
The study found that combinations of paclitaxel (PAC) and withaferin A (WFA) are highly synergistic against human non-small cell lung cancer cells, showing greater sensitivity than either treatment alone. WFA was active against PAC-sensitive and PAC-resistant NSCLC cells, demonstrating its potential therapeutic efficacy.
Prostate cancer death rates in the EU are expected to fall, but Poland's rates are rising. Women's lung and pancreatic cancer death rates continue to climb. The European Society for Medical Oncology predicts these trends will impact cancer mortality.
Patients with lung cancer in China who knew their diagnosis survived longer than those who did not, with a median survival time of 18.33 months versus 8.77 months. The study suggests that full disclosure of cancer diagnoses can benefit patients in the long term with proper communication and support.
Research published in Thorax journal found a heightened risk of lung cancer in people with COPD who have never smoked. The risk is comparable to that of smokers without chronic lung disease, suggesting early detection may reduce treatment complications.
Researchers developed a new approach to detecting lung cancer using nanoparticles that can interact with enzymes linked to the disease. The sensors were tested in mice and found to accurately detect tumors at an early stage, reducing false positives.
Researchers at MD Anderson Cancer Center propose using glucose transporter inhibitors to treat tumors with high expression of the SLC7A11 amino acid transporter. This approach targets cancer cells' dependency on glucose for survival, selectively killing 'addicted' cells.
Researchers at Moffitt Cancer Center found that targeting histone deacetylase HDAC11 blocks cancer stem cell self-renewal and overcomes drug resistance in non-small cell lung cancer. The study suggests that HDAC11 inhibitors may be a potential therapeutic strategy for NSCLC.
A recent study published in the Journal of Thoracic Oncology found that lung cancer clinical trials funded by the pharmaceutical industry demonstrate no more bias compared to studies funded by other sources. The analysis, led by Dr. Pedro Aguiar, assessed 477 studies and found that pharmaceutical-backed trials had stronger evidence, ev...
Researchers at NYU Abu Dhabi have developed a microfluidic platform that allows for the isolation and study of circulating tumor cells (CTCs) from blood samples. The platform enables high precision analysis of CTCs' mechanical properties at the single cell level, holding potential for early cancer detection and monitoring.
Research finds that people with a history of cancer are at over two-fold risk of developing atrial fibrillation (AFib), a heart rhythm disorder. Prostate cancer is most strongly associated with AFib, followed by colon, lung and breast cancers.
A UK study emphasizes the significance of spirometry in identifying chronic obstructive pulmonary disease (COPD), particularly among patients with respiratory symptoms. The study found that over-reliance on radiological changes alone may lead to incorrect diagnoses, highlighting the need for comprehensive assessments.
A University of Colorado Cancer Center study found that African American patients were half as likely as non-Hispanic whites to receive PET-CT imaging for non-small cell lung cancer, while Hispanics received it 70% as frequently. This disparity may be due to limited access to specialized imaging equipment and unconscious bias.
A study found that low-dose chest CT scans used for lung cancer screening do not cause significant DNA damage or chromosome aberrations. The results suggest that the risks of low-dose CT are minimal, and it can be used for lung cancer screening.
Including smoking cessation with existing lung cancer screening efforts would significantly reduce lung cancer mortality and increase life-years gained. The study found that point-of-screening cessation interventions could further reduce lung cancer deaths by 14% and increase life-years gained by 81%.
A study has described the pathology of SARS-CoV-2, or COVID-19, for the first time in its early phase. The research reveals edema, proteinaceous exudate, and inflammatory cellular infiltration in patients with COVID-19 pneumonina.
Researchers at University of Pennsylvania developed a blood test that correlates tumor mutations with clinical outcomes. Patients with higher mutation rates experience better responses to PD-1-based immunotherapy and longer survival times.
Researchers have identified two leukemia drugs that could be used to treat lung cancer patients with triple mutant EGFR, a type of non-small cell lung cancer. The drugs, gilteritinib and midostaurin, were found using a new live cell-based method developed by the University of Toronto team.
Researchers at Yale Cancer Center discovered that a small amount of the PD-L1 biomarker can predict long-term survival benefits from using pembrolizumab in patients with advanced lung cancer. The study found that overall survival was about 99% one year after discontinuing treatment, and ranged from 23% to 35% three years after treatment.
A team of researchers has identified new biomarkers for the diagnosis and prognosis of lung cancer by analyzing repetitive DNA regions. These markers show consistent expression in both healthy cells and cancerous tumors, with potential applications for more accurate diagnoses and treatments.
A study of over 925,000 adults with new cancer diagnoses found that Medicaid expansion improved insurance status, led to earlier cancer stage detection, and resulted in timely treatment. The findings suggest a positive association between Medicaid expansion and cancer care outcomes.
Researchers identified a molecule that maintains a healthy balance of airway basal stem cells and mature mucociliary cells, potentially leading to new treatments for lung cancer. The compound, Wnt Inhibitor Compound 1 (WIC1), has been shown to limit the proliferation of basal stem cells and restore balance in human cells.
Thoracic radiation therapy increases fatigue and difficulty breathing in cancer patients, but engaging in physical activity prior to treatment may help improve these symptoms over time. High levels of physical activity are associated with concurrent improvements in fatigue and shortness of breath.
Researchers discovered that combining alectinib with EGFR-inhibitors prevents CNS metastasis progression in mouse model. This combination treatment overcomes alectinib resistance, offering potential novel therapies for NSCLC and secondary cancers.
A Phase 2 clinical trial demonstrated improved localization and complete removal of small and peripheral lesions in 12% of patients. The treatment, OTL38, targets adenocarcinomas of the lung and has received fast-track designation for both lung and ovarian cancer indications.
A recent study across 40 countries found higher lung cancer rates in young women compared to men, driven by a rise in adenocarcinoma. Historically, lung cancer was more prevalent among men due to earlier smoking habits, but the gap is narrowing in some regions.
Researchers at USC have developed a new imaging technique called spectrally encoded enhanced representations (SEER) that provides greater clarity and works up to 67 times faster than existing methods. This technology has the potential to revolutionize disease diagnosis, particularly in detecting lung cancer and damage from pollutants.
Researchers found niche mutations to have higher mortality than EGFR, but similar mortality to KRAS mutations. Next-generation sequencing helps identify a large panel of mutations for precise treatment selection.
A study by the University of Texas M. D. Anderson Cancer Center shows that a lung cancer screening decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population and results in informed decisions about lung cancer screening. The decision aid, which explains eligibility, risks, and benefits, encoura...
Chronic exposure to interleukin-1-beta promotes lung cancer metastasis by altering gene expression, enabling cancer cells to adopt a phenotype that facilitates distance organ colonization. The study provides new insights into the role of chronic inflammation in tumor progression and metastasis.
A study found that people who quit smoking have more genetically healthy lung cells than current smokers, with a lower risk of developing into cancer. These 'protective cells' can help protect against lung cancer and may even allow new, healthy cells to actively replenish the lining of airways.
A new tumor-highlighting technology called OTL38 enhances the visualization of lung cancer tissue, improving patient outcomes. Researchers found that OTL38 helped identify 10 additional cancers in 7 patients and improved margins for 26% of patients.
A study published in the British Journal of General Practice found an increase in shortness of breath and cough as the first symptoms reported by patients diagnosed with lung cancer. This suggests earlier detection, possibly due to awareness campaigns.
Researchers have discovered that inhibiting p38 reduces the growth of lung tumors in genetic mouse models. Lower levels of p38 in tumors are associated with a more favorable prognosis for patients.
The American Cancer Society's annual report on cancer rates and trends shows a steady 26-year decline in overall cancer mortality, with long-term drops in lung, colorectal, breast, and prostate cancers. Lung cancer death rates have dropped by 51% since 1990, with the most rapid progress in recent years.
Restoring p53 using synthetic mRNA nanoparticles delays the growth of lung and liver cancer cells and makes them susceptible to available cancer drugs. The approach may also make tumors more vulnerable to cancer drugs known as mTOR inhibitors.
A University of Kentucky-led coalition is partnering with employers to connect men in rural Kentucky with critical lung cancer prevention and control resources. The worksite intervention targets predominantly male employees in eight rural counties, providing tobacco treatment, lung cancer screenings, and smoke-free workplace policies.
The study found that higher doses of radiation and adding the drug cetuximab did not improve patient survival compared to standard of care chemoradiation. The 5-year overall survival estimate for the standard radiation dose arm was 32.1%, amongst the highest for Stage III NSCLC.
A community-based program enables patients to donate tumor tissue and blood samples for research, allowing researchers to study genetic and molecular makeup of tumors after treatment failure. Analysis reveals similar DNA mutations and varying protein biomarker expression among samples from the same patient.
The pooled analysis of three clinical trials shows entrectinib is effective in 77% of patients with ROS1+ NSCLC and 57% of patients with NTRK+ NSCLC, with significant response rates and progression-free survival times. Entrectinib's ability to penetrate brain metastases makes it a promising treatment for these patients.
Researchers identified novel respiratory cell changes in smokers and pre-cancerous tissue, which may lead to new therapies for lung cancer prevention. The study used single-cell genomics to analyze gene expression in cells from never and current smokers.
A new study found wide variations in surgery rates for early-stage lung cancer across US counties, with socioeconomic and healthcare delivery factors contributing to the gap. Counties with higher poverty rates, non-Hispanic black populations, and lower surgeon-to-population ratios had lower surgery rates.
A new study found that depression affects approximately one-third of newly diagnosed lung cancer patients, leading to severe symptoms such as pain, hopelessness, and impaired day-to-day functioning.
A study found that AI can accurately measure coronary artery calcium, a marker of heart disease, in patients getting lung cancer screening CT scans. The system uses deep learning to automate the assessment, making it easier for doctors to decide on preventative therapy.
Researchers at UT MD Anderson Cancer Center found TBK1 and its adaptor protein contribute to tumorigenesis when activated by growth factors. Targeting TBK1 inhibits tumor growth and promotes antitumor immunity in mouse models.
Researchers have found that anti-cancer agents with low-molecular weights cannot reach tumors effectively due to obstructed small arteries. This limits the use of conventional chemotherapy and highlights the need for new treatments, according to Professor Tetsuya Kodama.
Researchers developed nanoparticles that can deliver immunostimulants via inhalation to induce systemic immune response against lung cancer. The treatment converted cold tumors to hot, immune-responsive tumors and showed significant regression of tumors in both lungs and prolonged survival of mice.
Researchers aim to reduce malnutrition among lung cancer patients by providing nutritional counseling and medically tailored meals. The study, funded by Bristol-Myers Squibb Foundation, will recruit up to 150 newly diagnosed patients with lung cancer across four medical centers.
A deep convolutional neural network-based software improved radiologist detection of malignant lung nodules by 70.3%, reducing false positives to 0.18 per X-ray. The study suggests machine learning methods can help overcome challenges in detecting lung lesions on chest X-rays.
Researchers at Stanford and UC-San Francisco have developed an experimental drug that targets lung cancer by neutralizing a single protein, slowing its growth. The decoy version of the receptor protein was engineered to preferentially bind to the protein, repelling other proteins involved in tumor growth.
The American College of Physicians (ACP) has released a new guidance statement for colorectal cancer screening in average-risk adults between 50 and 75 years old. The guidance suggests that physicians select the most suitable screening test for each patient based on factors such as benefits, harms, costs, availability, frequency, and p...
Researchers analyzed BTB and BBB changes in NSCLC brain metastasis over time, revealing key changes including loss of aquaporin-4 and zona occludens-1. These findings provide a comprehensive analysis of the transition of the blood-brain barrier to the blood-tumor barrier.
A high-fiber and yogurt-rich diet has been shown to reduce lung cancer risk by 33% compared to a low-fiber diet. The study's findings support the US Dietary Guidelines recommending a high fiber and yogurt diet for cardiovascular health and gastrointestinal cancer prevention.
A study of over 14,000 participants found associations between specific cigarette characteristics and lung cancer outcomes. Researchers analyzed data from a lung screening trial to investigate the impact of cigarette filter status, tar level, and menthol flavor on lung cancer outcomes.
Screening for ever-smokers with high lung cancer risk and long life-expectancy can prevent more deaths than current guidelines. A new study suggests using gains in life expectancy as a criterion to select candidates for screening, which could improve the balance of benefits and harms.
A new study presented at the IASLC 2019 North America Conference on Lung Cancer found that lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders. Low-dose computed tomography was shown to detect disease earlier in this population.
Researchers have discovered that patients' blood samples and tumour biopsies can reveal early signs of lung cancer spreading and becoming untreatable. The TRACERx project has identified possible causes of recurrence and developed new techniques to predict tumour aggression.